Tolcapone improves sleep in patients with advanced Parkinson's disease (PD)

Archives of Gerontology and Geriatrics

Volumn 51, Issue 3, 2010, Pages

  Ebersbach, Georg ^a   Hahn, Kirsten ^a   Lorrain, Michael ^b   Storch, Alexander ^c  

^a Movement Disorder Clinic   (Germany)

^b Private Practice   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

COMT inhibitor; Daytime sleepiness; Parkinson's disease; Sleep quality; Tolcapone

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; TOLCAPONE;

ADJUVANT THERAPY; ADULT; AGED; AKINESIA; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DELIRIUM; DIARRHEA; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EPWORTH SLEEPINESS SCALE; FEMALE; GLOBAL CLINICAL IMPRESSION OF CHANGE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SIDE EFFECT; SLEEP; SLEEP DISORDER; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOPHENONES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SLEEP DISORDERS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77957375419     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2010.03.008     Document Type: Article

References (39)

1. Askenasy J.J., Yahr M.D. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study. Neurology 1985, 35:527-532.
2. Baas H., Beiske A.G., Ghika J., Jackson M., Oertel W.H., Poewe W., Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the " wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry 1997, 63:421-428.
3. Bloch K.E., Schoch O.D., Zhang J.N., Russi E.W. German version of the Epworth Sleepiness Scale. Respiration 1999, 66:440-447.
4. Chaudhuri K.R., Pal S., Bridgman K., Trenkwalder C. Achieving 24-hour control of Parkinson's disease symptoms: use of objective measures to improve nocturnal disability. Eur. Neurol. 2001, 46(Suppl. 1):S3-S10.
5. Chaudhuri K.R., Pal S., Dimarco A., Whately-Smith C., Bridgman K., Mathew R., Pezzela F.R., Forbes A., Hogl B., Trenkwalder C. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2002, 73:629-635.
6. Comella C.L. Sleep disorders in Parkinson's disease: an overview. Mov. Disord. 2007, 22(Suppl. 17):S367-S373.
7. Comella C.L., Morrissey M., Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology 2005, 64:1450-1451.
8. Ebersbach G., Storch A. Tolcapone in elderly patients with Parkinson's disease: a prospective open-label multicenter non-interventional trial. Arch. Gerontol. Geriatr. 2009, 49:e40.
9. Factor S.A., McAlarney T., Sanchez-Ramos J.R., Weiner W.J. Sleep disorders and sleep effect in Parkinson's disease. Mov. Disord. 1990, 5:280-285.
10. Factor S.A., Molho E.S., Feustel P.J., Brown D.L., Evans S.M. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. 2001, 24:295-299.
11. Fahn S., Elton R., Committee U.D. The Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease 1987, 153-163. Macmillan Healthcare Information, Florham Park. S. Fahn, C.D. Marsden, D. Calne (Eds.).
12. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
13. Garcia-Borreguero D., Larrosa O., Bravo M. Parkinson's disease and sleep. Sleep Med. Rev. 2003, 7:115-129.
14. Hauser R.A., Gauger L., Anderson W.M., Zesiewicz T.A. Pramipexole-induced somnolence and episodes of daytime sleep. Mov. Disord. 2000, 15:658-663.
15. Hogl B., Rothdach A., Wetter T.C., Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003, 28:1866-1870.
16. Jansen E.N., Meerwaldtt J.D. Madopar HBS in nocturnal symptoms of Parkinson's disease. Adv. Neurol. 1990, 53:527-531.
17. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
18. Jorga K., Fotteler B., Sedek G., Nielsen T., Aitken J. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J. Neurol. 1998, 245:223-230.
19. Koller W., Lees A., Doder M., Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 2001, 16:858-866.
20. Lees A.J. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci. Ther. 2008, 14:83-93.
21. Lees A.J., Ratziu V., Tolosa E., Oertel W.H. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:944-948.
22. Martinez-Martin P., Salvador C., Menendez-Guisasola L., Gonzalez S., Tobias A., Almazan J., Chaudhuri K.R. Parkinson's Disease Sleep Scale: validation study of a Spanish version. Mov. Disord. 2004, 19:1226-1232.
23. Olanow C.W., Watkins P.B. Tolcapone: an efficacy and safety review (2007). Clin. Neuropharmacol. 2007, 30:287-294.
24. Pahwa R., Busenbark K., Huber S.J., Michalek D., Hubble J.P., Koller W.C. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993, 43:677-681.
25. Paus S., Brecht H.M., Koster J., Seeger G., Klockgether T., Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 2003, 18:659-667.
26. Poewe W. Psychosis in Parkinson's disease. Mov. Disord. 2003, 18(Suppl. 6):S80-S87.
27. Poewe W., Hogl B. Parkinson's disease and sleep. Curr. Opin. Neurol. 2000, 13:423-426.
28. Poewe W., Seppi K. Managing the non-motor symptoms of Parkinson's disease. Therapeutics of Parkinson's Disease and Other Movement Disorders 2008, 91-120. Wiley-Blackwell, Chichester. M. Hallett, W. Poewe (Eds.).
29. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., Rupp M., Boroojerdi B. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007, 6:513-520.
30. Rajput A.H., Martin W., Saint-Hilaire M.H., Dorflinger E., Pedder S. Tolcapone improves motor function in parkinsonian patients with the " wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997, 49:1066-1071.
31. Rye D.B. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 2006, 6:169-176.
32. Scaravilli T., Gasparoli E., Rinaldi F., Polesello G., Bracco F. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol. Sci. 2003, 24:209-210.
33. Schrag A., Selai C., Jahanshahi M., Quinn N.P. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2000, 69:67-73.
34. Shulman L.M., Taback R.L., Rabinstein A.A., Weiner W.J. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:193-197.
35. Stocchi F., Barbato L., Nordera G., Berardelli A., Ruggieri S. Sleep disorders in Parkinson's disease. J. Neurol. 1998, 245(Suppl. 1):S15-S18.
36. Tandberg E., Larsen J.P., Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord. 1998, 13:895-899.
37. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group. Clin. Neuropharmacol. 1989, 12:498-505. The U.K. Madopar CR Study Group.
38. Tracik F., Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings. Mov. Disord. 2001, 16:500-506.
39. Trenkwalder C., Hoegl M., Kohnen R., Sixel-Doering F., Frauscher B., Schoerling A., Martinez-Martin P., Poewe W., Chaudhuri K.R. The Parkinson's disease sleep scale (PDSS) modified-preliminary results from a validation study. Mov. Disord. 2009, 23:S356.